Among these genes, BBC3 has been reported to be associated with cisplatin resistance in ovarian cancer (Zhang et al., 2012; Grozav et al., 2015), and has been proposed as a chemosensitizer in platinum compounds-based ovarian cancer therapy (Yuan et al., 2011). This evidence concerns the gene BBC3 and ovarian cancer.